HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK | Zendy

Kate El Bouzidi | Zendy; Ellen White | Zendy; Jean L. Mbisa | Zendy; Caroline Sabin | Zendy; Andrew Phillips | Zendy; Nicola Mackie | Zendy; Anton Pozniak | Zendy; Anna Tostevin | Zendy; Deenan Pillay | Zendy; David Dunn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK

Author(s) -

Kate El Bouzidi,

Ellen White,

Jean L. Mbisa,

Caroline Sabin,

Andrew Phillips,

Nicola Mackie,

Anton Pozniak,

Anna Tostevin,

Deenan Pillay,

David Dunn

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw343

Subject(s) - darunavir , medicine , drug resistance , genotype , hiv drug resistance , cohort , oncology , human immunodeficiency virus (hiv) , immunology , genetics , biology , viral load , antiretroviral therapy , gene

Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials. However, there is little information on DRMs that are directly selected by darunavir in clinical settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research